Molecular mechanisms in hepatocellular carcinoma development

被引:90
|
作者
Cha, C
DeMatteo, RR
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatobiliary Serv, New York, NY 10021 USA
[2] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA
关键词
hepatocellular carcinoma; molecular; tumor suppressor genes; p53; oncogenes; hepatitis B virus; hepatitis C virus; aflatoxin; cirrhosis;
D O I
10.1016/j.bpg.2004.11.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. It usually develops in patients with chronic viral hepatitis, aflatoxin exposure, or excessive alcohol use. Most patients with HCC present with advanced disease and have a poor prognosis. The implementation of antiviral drugs and the availability of a vaccine for hepatitis B should help reduce the incidence of HCC. Considerable effort has now focused on unraveling the molecular pathogenesis of HCC in order to design better treatments, or to prevent the disease altogether. However, so far, the pathogenesis of HCC appears to be quite heterogenous among patients. In particular, several mechanisms of tumorigenesis seem to be involved, including loss of tumor suppressor gene function, oncogene activation, direct viral effects, DNA methylation, and angiogenesis. It is not clear which events are critical in tumor initiation versus tumor progression. RNA expression arrays and proteomics hold promise to provide further clues about this common and complex cancer.
引用
收藏
页码:25 / 37
页数:13
相关论文
共 50 条
  • [31] Molecular mechanisms of pathogenesis in hepatocellular carcinoma revealed by RNA-sequencing
    Liu, Yao
    Yang, Zhe
    Du, Feng
    Yang, Qiao
    Hou, Jie
    Yan, Xiaohong
    Geng, Yi
    Zhao, Yaning
    Wang, Hua
    MOLECULAR MEDICINE REPORTS, 2017, 16 (05) : 6674 - 6682
  • [32] Elucidation of the molecular mechanisms mediating sorafenib-resistance in Hepatocellular carcinoma
    Vishnoi, Kanchan
    Ke, Rong
    Kumar, Randhir
    Viswakarma, Navin
    Rana, Ajay
    Rana, Basabi
    CANCER RESEARCH, 2020, 80 (16)
  • [33] Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities
    Abhiram Natu
    Anjali Singh
    Sanjay Gupta
    World Journal of Hepatology, 2021, (11) : 1568 - 1583
  • [34] Roles and Molecular Mechanisms of Biomarkers in Hepatocellular Carcinoma with Microvascular Invasion: A Review
    Zhao, Xudong
    Wang, Yudan
    Xia, Haoming
    Liu, Shuqiang
    Huang, Ziyue
    He, Risheng
    Yu, Liang
    Meng, Nanfeng
    Wang, Hang
    You, Junqi
    Li, Jinglin
    Yam, Judy Wai Ping
    Xu, Yi
    Cui, Yunfu
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (05) : 1170 - 1183
  • [35] Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities
    Natu, Abhiram
    Singh, Anjali
    Gupta, Sanjay
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (11) : 1568 - 1583
  • [36] Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma
    Li, Heping
    Hu, Jie
    Qiu, Lijie
    Wu, Yijiang
    Zhong, Baiyin
    Ye, Rong
    Xie, Binhui
    ANTI-CANCER DRUGS, 2024, 35 (01) : 55 - 62
  • [37] Therapeutic Value of Estrogen Receptor α in Hepatocellular Carcinoma Based on Molecular Mechanisms
    Meng, Xiangzhe
    Liu, Xue
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (01) : 140 - 146
  • [38] Molecular mechanisms of Codonopsis pilosula in inhibiting hepatocellular carcinoma growth and metastasis
    Li, Ning
    Yang, Ce
    Xia, Jing
    Wang, Wenxiang
    Xiong, Wei
    PHYTOMEDICINE, 2024, 128
  • [39] Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma
    Vescovo, T.
    Refolo, G.
    Vitagliano, G.
    Fimia, G. M.
    Piacentini, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (10) : 853 - 861
  • [40] Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma
    Tian, Yichen
    Lei, Yongrong
    Fu, Yuna
    Sun, Heng
    Wang, Jianhua
    Xia, Feng
    CURRENT CANCER DRUG TARGETS, 2022, 22 (06) : 454 - 462